Send to

Choose Destination
J Natl Compr Canc Netw. 2017 Jul;15(7):883-893. doi: 10.6004/jnccn.2017.0117.

NCCN Guidelines Insights: Antiemesis, Version 2.2017.

Author information

From The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Vanderbilt-Ingram Cancer Center; Duke Cancer Institute; University of Wisconsin Carbone Cancer Center; Fred & Pamela Buffett Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; Moffitt Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Stanford Cancer Institute; Huntsman Cancer Institute at the University of Utah; Fox Chase Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; City of Hope Comprehensive Cancer Center; Mayo Clinic Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; The University of Texas MD Anderson Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; UC San Diego Moores Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; Memorial Sloan Kettering Cancer Center; Roswell Park Cancer Institute; University of Michigan Comprehensive Cancer Center; and National Comprehensive Cancer Network.


The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Antiemesis address all aspects of management for chemotherapy-induced nausea and vomiting. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Antiemesis, specifically those regarding carboplatin, granisetron, and olanzapine.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center